Posted by Michael Wonder on 05 Mar 2026
New multi-indication PBS listing for two immunotherapy treatments from March 2026
1 March 2026 - Bristol Myers Squibb Australia confirms that Opdivo (nivolumab) and Yervoy (ipilimumab) will be listed on the PBS for the treatment of immunotherapy sensitive advanced or metastatic cancer from March 2026.
Under this new listing, the PBAC has recommended that clinicians use clinical judgement and discretion, guided by the best available clinical evidence, to determine if a person living with immunotherapy-sensitive advanced or metastatic cancer may benefit from nivolumab and/or ipilimumab.
